| HOME >> BIOLOGY >> TECHNOLOGY |
WILMINGTON, Mass., March 17 /PRNewswire/ -- OmniSonics Medical Technologies, Inc., a developer of advanced medical devices for use in the treatment of vascular disease, announced today that it has enrolled its first patient in the SONIC I Clinical Registry. SONIC I is a prospective, multi-centered U.S. registry study of the company's OmniWave(TM) Endovascular System (OES) in patients undergoing percutaneous mechanical thrombectomy of acute deep vein thrombosis (DVT). All patients enrolled in the SONIC I are scheduled for follow-up at 30 days and 6 months following the OmniWave procedure. The first patient was enrolled by Daniel Clair, M.D., Chairman of Vascular Surgery at The Cleveland Clinic.
"The Cleveland Clinic is excited to participate in the SONIC I clinical trial with the OmniWave Endovascular System," said Dr. Clair. "The OmniWave System has the potential to offer physicians an effective alternative to current pharmacological and mechanical treatments for deep vein thrombosis (DVT)."
In response to this important milestone, Richard Ganz, President and CEO of OmniSonics Medical Technologies, said, "We continue to be encouraged by the positive outcomes the first physicians are having with the OmniWave Endovascular System. Enrolling our first patient in the SONIC I Clinical Registry is a key step in our contribution to providing tools to physicians for the treatment of DVT."
In September 2007, OmniSonics received clearance from the Food and Drug Administration (FDA) to market its catheter-based OmniWave Endovascular System for the infusion of physician specified fluids, including thrombolytics, and for the removal of thrombus in the peripheral vasculature.
OmniSonics Medical Technologies, Inc. is scheduled to exhibit the OmniWave Endovascular System at the Society for Interventional Radiology (SIR) Meeting to be held March 15-20 in Washington, DC.
The OmniWave Endovascular System is based on patented OmniWave
technology
'/>"/>
| SOURCE OmniSonics Medical Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
4. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
5. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
6. First-Ever Cancer and Careers Seminar Debuts in Orange County
7. Pharmaxis First Steps into China
8. NIOXIN(R) Delivers the Future to Scalp and Hair Care, Introduces the First Genetic Test to Determine the Likelihood of Hair Loss
9. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
10. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
11. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |